NDAOPHTHALMICSOLUTION/DROPSPriority Review
Approved
Jun 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ISOPTO CARPINE (pilocarpine hydrochloride) is a small-molecule ophthalmic solution used to treat glaucoma and ocular hypertension by stimulating cholinergic receptors to increase aqueous humor outflow. It is a direct-acting parasympathomimetic agent that has been a standard-of-care option in eye care for decades. The drug is administered as topical eye drops.
LOE Approaching
As LOE approaches, the brand team is likely consolidating and shifting focus to line extensions or exit planning; field roles may see reduced headcount.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ISOPTO CARPINE offers limited career growth due to its LOE-approaching status and minimal job pipeline (0 linked positions). Professionals on this product should expect consolidation, potential layoffs, or internal redeployment as the brand transitions post-LOE.
Brand ManagerProduct Manager
Worked on ISOPTO CARPINE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.